Loading...
•
Dec 31, 2020
Mersana Q4 2020 Earnings Report
Mersana Therapeutics reported financial results for the fourth quarter and full year 2020 and provided a business update.
Key Takeaways
Mersana Therapeutics reported its Q4 and full year 2020 financial results, highlighting the progress of UpRi in ovarian cancer and advancements in its ADC pipeline. The company ended the year with $255.1 million in cash and expects these funds to support its operating plan for approximately the next two years.
UpRi single-arm registration strategy (UPLIFT) in platinum-resistant ovarian cancer is on track to begin in Q1 2021.
Significantly progressed pipeline of ADC candidates from the Company’s innovative Dolasynthen and Immunosynthen platforms.
Ended 2020 with $255.1 million in cash.
Net cash used in operating activities in the fourth quarter of 2020 was $17.3 million.
Forward Guidance
Mersana expects that its available funds will be sufficient to support its operating plan commitments for approximately the next two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...